Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled pirfenidone for idiopathic pulmonary fibrosis
IRCT20170531034256N4Phase 2Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of pirfenidone in idiopathic pulmonary fibrosis (IPF), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Forced vital capacity, Respiratory function indices and 4 more. Started May 2025; status: completed.
02
Drugs
pirfenidone
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on IRCT20170531034256N4.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170531034256N4.